EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Insights into Multiple Myeloma: Immune Microenvironment, Disease Mechanisms, and Therapeutic Innovations

Takahiko Miyama, Keichiro Mihara

International Journal of Molecular Sciences · 13.11.2026 · 27 (22) · 10183

DOI: 10.3390/ijms272210183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.11.2026. Verfasst von Takahiko Miyama und 1 weiteren Autor:innen. Die Arbeit nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujita Research Grant.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) remains a hematologic malignancy characterized by progressive immune dysfunction and the emergence of therapeutic resistance despite substantial recent advances in treatment. The transition from monoclonal gammopathy of undetermined significance (MGUS) to symptomatic MM is associated with coordinated immune dysfunction across innate and adaptive immune compartments. Single-cell and spatial profiling technologies reveal that immune abnormalities emerge at precursor stages and intensify during progression, including T-cell exhaustion, expansion of regulatory T cells, natural killer cell dysfunction, and impaired antigen presentation by dendritic cells. The cancer immunoediting framework, encompassing elimination, equilibrium, and escape phases, provides a unifying paradigm for understanding tumor-immune coevolution in MM. Disease complexity is further compounded by pronounced spatial and temporal heterogeneity. Multi-region sequencing studies demonstrate anatomically distinct clonal architectures and immune microenvironments within individual patients, contributing to variable therapeutic responses and facilitating immune escape. Current immunotherapies, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, chimeric antigen receptor (CAR) T-cell therapies, and bispecific antibodies, have transformed the therapeutic landscape of MM. Nevertheless, durable disease control remains limited by convergent resistance mechanisms, including antigen modulation, T-cell dysfunction, and persistent microenvironmental immunosuppression. A comprehensive understanding of the immune-mediated resistance mechanisms, extending beyond tumor-intrinsic genetic alterations, is essential for the rational design of next-generation therapies. Accumulating evidence suggests that immune dysfunction is closely associated with disease evolution and treatment resistance in MM and may represent a potentially targetable contributor to these processes.

Förderung

  • Fujita Research Grant

Zitieren

APA

Miyama, T., & Mihara, K. (2026). Insights into Multiple Myeloma: Immune Microenvironment, Disease Mechanisms, and Therapeutic Innovations. International Journal of Molecular Sciences, 27(22), 10183. https://doi.org/10.3390/ijms272210183

Vancouver

Miyama T, Mihara K. Insights into Multiple Myeloma: Immune Microenvironment, Disease Mechanisms, and Therapeutic Innovations. International Journal of Molecular Sciences. 2026;27(22):10183. doi:10.3390/ijms272210183

BibTeX
@article{Miyama2026,
  author = {Miyama, Takahiko and Mihara, Keichiro},
  title = {Insights into Multiple Myeloma: Immune Microenvironment, Disease Mechanisms, and Therapeutic Innovations},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {22},
  pages = {10183},
  doi = {10.3390/ijms272210183}
}
Kostenlos starten →